The role of Septin6 Group in Murine and Human Hematopoiesis
- Institution
- BOSTON CHILDREN'S HOSPITAL, MA
- Principal investigator
- David A Williams
- Funding
- $354K
- Duration
- 2023–2026
Moonbase score
Still being scored
Abstract
(PLEASE KEEP IN WORD, DO NOT PDF) Title: The role of Septin6 Group in Murine and Human Hematopoiesis 1 R01 DK137172-01 Septins are highly conserved GTPase proteins which regulate a variety of cellular functions including cytokinesis, polarity, cell cycle, vesicle trafficking, exocytosis, and creation of diffusion barriers. We have recently identified a non-syndromic newborn with severe neutropenia (Renella, AJH 2022) with a novel X-linked germline mutation in the C-terminus of SEPTIN6 gene (SEPTIN6 c.1282T>C p.428Glnext*9) associated with dysmyelopoiesis. Editing the germline mutation into normal male CD34+ hematopoietic stem and progenitor cells (HSC/P) phenocopied key pathologic features of the clinical syndrome, including large, multinucleated nuclei and reduced myeloid progenitor growth in vitro (preliminary data). The C-terminus has been proposed to play a key role in filament stabilization, bundling and bending as well as interactions with other septins and in silico modeling suggest the addition of 9 amino acids (aa) associated with the SEPTIN6 c.1282T>C p.428Glnext*9 mutation would alter function by interfering with SEPTIN6 protein interactions. Based on our initial publication, a second patient with severe neutropenia has since been identified in Seattle with a distinct mutation in the same codon (SEPTIN6 c.1282T>A) (Mohamad, Allensbach, Williams, accepted for presentation, ASH 2022). While the aa substitution is different, modeling predicts that SEPTIN6 variants adopt the same structure. Both identified patients had a high degree of myeloid tetraploidy in the marrow and were refractory to G-CSF.
LOADING MOONBASE SCORE
Questions for BOSTON CHILDREN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Boston Children'S HospitalNot yet scored
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
Michael A Pulsipher · $705K · 2022–2029
- NIH · University of Michigan at Ann ArborNot yet scored
University of Michigan (UM) HEAL Initiative National K12 Clinical Pain Career Development Program (UM-HCPDP)
Daniel J Clauw · $3.1M · 2022–2027
- NIH · Boston Children'S HospitalNot yet scored
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector
David A Williams · $1.3M · 2016–2029